In the latest close session, Novavax (NVAX) was up +1.01% at $8.01. The stock outperformed the S&P 500, which registered a daily gain of 0.29%. Elsewhere, the Dow lost 0.31%, while the tech-heavy ...

GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern ...

Novavax (NVAX) is in focus after outlining a move toward a licensing and royalty model, supported by partnerships with Sanofi and Pfizer, while investors watch for a Phase 3 COVID influenza combo ...

If you are wondering whether Novavax at around US$8.22 is a bargain or a value trap, the key is understanding what the current price actually reflects. The stock has been volatile, with a 7 day return ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, ...

Add Yahoo as a preferred source to see more of our stories on Google. Food and Drug Administration commissioner Martin Markary speaks during an event in the Roosevelt Room at the White House, Monday, ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...

The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...

Wondering whether Novavax at about US$7.98 is a bargain or a value trap? This article walks through the key signals that matter for you. The stock has had a mixed run, with a 2.0% decline over the ...

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...